Taisho Pharmaceutical Holdings Co., Ltd. (TAISF)

37,25 0,00 (0,00%) Alla chiusura: 10:36AM EDT

Taisho Pharmaceutical Holdings Co., Ltd.

3-24-1 Takada
Toshima-ku
Tokyo 170-8655
Japan
81 3 3985 2020
https://www.taisho-holdings.co.jp

Settore/i: 
Settore: 
Impiegati a tempo pieno: 9.134

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Akira Uehara	CEO & Representative Director	719,35k	N/D	1941
Mr. Ken Uehara	MD & Exec. Director	645,19k	N/D	N/D
Mr. Shigeru Uehara	Exec. VP & Director	793,51k	N/D	N/D
Shinichi Tanaka	Gen. Mang. of Corp. Communications	N/D	N/D	N/D
Mr. Tetsu Watanabe	Exec. Director	N/D	N/D	N/D
Mr. Jun Kuroda	Exec. VP & Director	N/D	N/D	1958
Hideki Iuchi	Gen. Mang.	N/D	N/D	N/D
Jinsei Maruyama	Corp. Officer	N/D	N/D	N/D
Hisashi Umeoka	Director	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Taisho Pharmaceutical Holdings Co., Ltd., through its subsidiaries, researches, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) drugs and prescription pharmaceutical products in Japan and internationally. It operates through Self-Medication Operation Group and Prescription Pharmaceutical Operation Group segments. The Self-Medication Operation Group segment offers OTC drugs, quasi-drugs, food products, and general medical and hygiene supplies, such as Lipovitan series of energy drinks; the Pabron series of cold remedies and sinus treatments; the RiUP series of hair re-growth treatment products; the Taisho Kampo series of gastrointestinal treatment products; the Colac series of laxative products; the Naron series and other products for antipyretic analgesics; the Preser series of hemorrhoid treatment products; Hapacol, Efferalgan, Dafalgan, and Tempra for antipyretic analgesics; Counterpain topical anti-inflammatory analgesics; Vitacilina, a dermatological treatment product; and VICKS, a cough suppressant throat lozenges and medicated drops. This segment also engages in the real estate leasing and facility management, and hotel management operations. The Prescription Pharmaceutical Operation Group segment offers ethical drugs, including Edirol, an active vitamin D3 osteoporosis agent; Clarith, a macrolide antibiotic; Palux, a peripheral vasodilator; Bonviva, a bisphosphonate osteoporosis agent; Lusefi, a type 2 diabetes mellitus agent; and LOQOA, a transdermal anti-inflammatory analgesic. This segment has various products under development primarily in therapeutic areas, such as central nervous system, infectious, and metabolic diseases, as well as orthopedic disorders. The company also offers raw materials for pharmaceuticals and quasi-drugs; and supplies health foods and skin care products. Taisho Pharmaceutical Holdings Co., Ltd. was founded in 1912 and is headquartered in Tokyo, Japan.

Governance aziendale

L'ISS Governance QualityScore di Taisho Pharmaceutical Holdings Co., Ltd. al 31 luglio 2022 è 10. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 10; diritti degli azionisti: 10; retribuzione: 8.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.